Clinical fate of reversible non-ischemic left ventricular systolic dysfunction and its influencing factors

Korean Circulation Journal

Volumn 36, Issue 1, 2006, Pages 53-59

  Moon, Jeong Geun ^a   Rim, Se Joong ^a   Shim, Jaemin ^a   Ahn, Chul Min ^a   Kang, Shin Ae ^a   Park, Sungha ^a   Choi, Eui Young ^a   Ko, Young Guk ^a   Kang, Seok Min ^a   Ha, Jong Won ^a   Jang, Yangsoo ^a   Chung, Namsik ^a   Cho, Seung Yun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Congestive heart failure; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN;

ADULT; AGED; ALCOHOLIC CARDIOMYOPATHY; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOXORUBICIN INDUCED CARDIOMYOPATHY; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; PROGNOSIS; RECURRENT DISEASE; TACHYCARDIA;

EID: 33644586319     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2006.36.1.53     Document Type: Article

References (24)

1. O'connell JB, Bristow M. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:5107-12.
2. Chang HJ, Chung J, Choi JH, et al. Prognostic value of C-reactive protein in patients with non-ischemic dilated cardiomyopathy: prospective study. Korean Circ J 2003;33:355-61.
3. Hunt SH, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 2001;38:2101-13.
4. McLaran CJ, Gersh BJ, Sugrue DD, Hammill SC, Seward JB, Holmes DR Jr. Tachycardia induced myocardial dysfunction: a reversible phenomenon? Br Heart J 1985;53:323-7.
5. Anselme F, Boyle N, Josephson M. Incessant fascicular tachycardia: a cause of arrhythmia induced cardiomyopathy. Pacing Clin Electrophysiol 1998;21:760-3.
6. Chung N, Jang Y, Ha JW, et al. Analysis of the left ventricular contractile reserve using end-systolic pressure-volume relation (ESPVR) in idiopathic dilated cardiomyopathy: its correlation with pathologic findings. Korean Circ J 1999;29:751-61.
7. Mobini R, Maschke H, Waagstein F. New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanism and therapy. Autoimmun Rev 2004;3:277-84.
8. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic dilated cardiomyopathy: a population based study. Ann Intern Med 1992;117:117-23.
9. Cetta F, Michels VV. The natural history and spectrum of idiopathic dilated cardiomyopathy including HIV and peripartum cardiomyopathy. Curr Opin Cardiol 1995;10:332-8.
10. Khanlou H, Paltoo B, Forbes W. Echocardiographic parameters in reversible idiopathic dilated cardiomyopahty. Am J Med Sci 2000;319:366-9.
11. Schwarz F, Mall G, Zebe H, et al. Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics. Circulation 1984;70:923-8.
12. Mann-Rouillard V, Fishbein MC, Naqvi TZ, DonMichael TA, Seigel RJ. Frequency of echocardiographic normalization of heart size and contractility in idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:131-3.
13. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden cardiac death in patients with tachycardia: induced cardiomyopathy and recurrent tachycardia. Circulation 2004;110:247-52.
14. Kuwata A, Ohashi M, Sugiyama M, Ueda R, Dohi Y. A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma. Am J Med Sci 2002;324:331-4.
15. Danaher PJ, Cao MK, Anstead GM, Dolan MJ, DeWitt CC. Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 2004;53:15-7.
16. Kontani M, Izumiya Y, Shimizu M, et al. Acute reversible myocardial depression associated with sepsis. Intern Med 2003;42:60-5.
17. Avsar A, Dogan A, Tavli T. A rare cause of reversible dilated cardiomyopathy: hypocalcemia. Echocardiography 2004;21:609-12.
18. Bezdah L, Slimene H, Kammoun M, Haddad A, Belhani A. Hypothyroid dilated cardiomyopathy. Ann Cardiol Angeiol 2004;53:217-20.
19. Phillips SD, Warnes CA. Peripartum cardiomyopathy: current therapeutic perspectives. Curr Treat Options Cardiovasc Med 2004;6:481-8.
20. Hong SK, Choi H, Lee SC, et al. Reversal of dilated cadiomyopathy with medical therapy in a case of pheochromocytoma. Korean Circ J 1998;28:284-90.
21. Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing induced dilated cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995;92:2306-17.
22. Takahashi M, Tsutsui H, Kinugawa S, et al. Role of microtubules in the contractile dysfunction of myocytes from tachycardia-induced dilated cardiomyopathy. J Mol Cell Cardiol 1998;30:1047-57.
23. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991;261:H308-18.
24. Han SW, Ryu KH, Chae SC, et al. Multicenter analysis of clinical characteristics and prognostic factors of patients with congestive heart failure in Korea. Korean Circ J 2005;35:357-61.